Dexcom Q1: strong growth and positive news

Atea (Buy, TP: NOK170.00) - Solid performance

Q1 gross profit and EBIT beat our above-consensus estimates, largely on a higher gross margin offsetting a slightly softer-than-expected top line and more opex than we expected. Furthermore, adjusted for FX losses, underlying earnings were well above our estimate and consensus. In short, we see this setting Atea up to track in line with our above-consensus estimates for 2025–2027 (which we have edged up) as well as multiples expansion. We reiterate our BUY, and have raised our target price to NO...

Nordic Semiconductor (Buy, TP: NOK160.00) - Not too bad given tail-end...

While implied guidance for H1 revenues is ~1–4% below our forecast and consensus, the underlying sequential performance is directionally in line with the broader set of peers to have reported to date. We find this growth and gross margin profile solid, given we are at the tail-end of the life of Nordic’s 10-year-old 55nm technology platform. Combined with the arguably unprecedented level of uncertainty for the company’s customers, we find it achieving a ~50% gross margin and accelerated Cellular...

Nordic Semiconductor ASA: 1 director

A director at Nordic Semiconductor ASA bought 20,090 shares at 102.500NOK and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...

Soft Q1 growth from Logitech

14% drop seems like an overreaction

Growth: check, margin: check, valuation: check

4% EBIT beat, solid 2025 guidance

Q1 beat, but muted Q2 guidance

Atea (Buy, TP: NOK160.00) - Set up for a strong run

While we have cut our estimates, we expect improving margins on recently launched frame agreements, continued hardware refresh cycles, and a potential shift in customer preferences for IT infrastructure deployment models to contribute to a return to double-digit EBIT growth, in line with or above its historical track record. Although there is clearly risk inherent in the ongoing trade war and recent competitive dynamics, Atea’s heavy exposure to the Nordic public sector should cushion it from su...

Growth to accelerate in 2025

Important year coming up

BioArctic AB: 3 directors

Three Directors at BioArctic AB bought 3,120 shares at between 163.200SEK and 164.700SEK. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

Nordic Semiconductor (Buy, TP: NOK174.00) - Near-term momentum likely ...

While the effects of trade tensions and tariff upheaval remain uncertain, our discussions with industry sources suggest strong, improving order momentum in Q1. Moreover, we expect the recently announced 90-day tariff pause to drive pull-forward of US imports. This has led us to shift our estimates from H2 towards H1. Beyond tariff-induced pull-ins, Dexcom channel replenishment dynamics remain one company-specific source of uncertainty to watch, while we estimate a limited effect. We remain sligh...

Mixed upside potential, despite market recovery expectations

Pent-up demand and falling interest rates remain the backbone for newbuild recovery expectations. However, as the recovery has not yet started, property developers screen as the most attractive long-term, but visibility remains mixed. Diversified construction companies are more attractive on near-term P/Es, although many seem to be fully valued on solid share-price performance over the past six months. We maintain a neutral sector view; NCC and Skanska are our top picks.

Two birds with one (very tiny) stone

Norway: Best ideas Q1'25

BioArctic (Buy, TP: SEK350.00) - Large milestones in 2025e

The Q4 report was slightly better than we expected. The royalty levels were already known, but the operating loss was below our forecast due to lower R&D and S&M spending. In 2025, BioArctic is set to receive cUSD130m in milestone payments from Bristol-Myers Squibb (due to the Brain Transporter deal) and Eisai (for EU approval as well as a sales milestone). The next important event is set to be the CHMP meeting in February that should (again) result in a positive opinion for Leqembi’s EU approva...

Some early signs of improvement

NRC Group (Hold, TP: NOK4.50) - Results will speak for themselves

With its weaker-than-expected Q4, NRC Group reiterated its 2025 guidance for revenue of NOK7bn and an adj. EBIT margin above 2%. However, as the company has missed its revenue guidance and EBIT margin targets for seven years in a row (2018–2024), we await evidence of an EBIT margin recovery. We remain cautious, and believe NRC is a high-risk/high-reward investment case, with ample upside potential should it reach its EBIT margin targets. We reiterate our HOLD, but have cut our target price to NO...